Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Non-Current Liabilities: 2014-2024

Historic Other Non-Current Liabilities for Vanda Pharmaceuticals (VNDA) over the last 11 years, with Dec 2024 value amounting to $9.6 million.

  • Vanda Pharmaceuticals' Other Non-Current Liabilities rose 18.55% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 18.55%. This contributed to the annual value of $9.6 million for FY2024, which is 8.61% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $9.6 million for FY2024, which was up 8.61% from $8.8 million recorded in FY2023.
  • Vanda Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $9.6 million for FY2024, and its period low was $2.8 million during FY2020.
  • In the last 3 years, Vanda Pharmaceuticals' Other Non-Current Liabilities had a median value of $8.8 million in 2023 and averaged $8.4 million.
  • Data for Vanda Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY spiked of 227.05% (in 2020) over the last 5 years.
  • Over the past 5 years, Vanda Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $2.8 million in 2020, then soared by 59.23% to $4.4 million in 2021, then soared by 54.90% to $6.8 million in 2022, then rose by 29.81% to $8.8 million in 2023, then climbed by 8.61% to $9.6 million in 2024.